Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension

Completed · Phase 3 · Has a placebo group

Conditions studied: Hypertension, Left Ventricular Hypertrophy, Overweight

In brief

To compare the efficacy and safety of aliskiren in combination with losartan compared to losartan on the regression of the increased size of the left ventricle in overweight patients with high blood pressure.

Key facts

Study ID

NCT00219141

Run by

Novartis Pharmaceuticals

People needed

460

Starts

2005-10-01

Expected to finish

2007-11-01

Last updated by the study team

2011-05-26

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with essential hypertension
• Patients with a BMI > 25 kg/m2
• Patients with LVH (LVWT ≥ 1.3 cm) confirmed by the ECHO

You may not qualify if…

• Patients treated with an ACE or an ARB within 3 months of study entry (Study Visit 1) who are unable or unwilling to undergo the 3 month washout period.
• Patients treated with an ACE and ARB combination at study entry.
• Known secondary hypertension of any etiology (e.g., uncorrected renal artery stenosis).
• Other protocol related inclusion/exclusion criteria applied to the study.

Where it is running

• Novartis Pharmaceuticals — East Hanover, New Jersey, United States
• sites in Argentina — Argentina, Argentina
• sites in Colombia — Colombia, Colombia
• sites in Finland — Finland, Finland
• sites in Germany — Germany, Germany
• sites in Italy — Italy, Italy
• sites in Russia — Russia, Russia
• sites in Spain — Spain, Spain
• sites in Sweden — Sweden, Sweden

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.